The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study

被引：0
|
作者：
Tiffany R. Lago
Michael J. Brownstein
Emily Page
Emily Beydler
Adrienne Manbeck
Alexis Beale
Camille Roberts
Nicholas Balderston
Eve Damiano
Suzanne L. Pineles
Neal Simon
Monique Ernst
Christian Grillon
机构：
[1] National Institute of Mental Health,National Center
[2] VA Boston Healthcare System,undefined
[3] Boston University School of Medicine,undefined
[4] Azevan Pharmaceuticals Inc,undefined
[5] University of Pennsylvania,undefined
[6] PTSD At VA Boston Healthcare System,undefined
[7] Lehigh University,undefined
来源：
Psychopharmacology | 2021年 / 238卷
关键词：
Fear-potentiated startle; Anxiety-potentiated startle; NPU threat test; Threat of shock; V1a receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2393 / 2403
页数：10
相关论文
共 16 条
  • [1] The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study
    Lago, Tiffany R.
    Brownstein, Michael J.
    Page, Emily
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Roberts, Camille
    Balderston, Nicholas
    Damiano, Eve
    Pineles, Suzanne L.
    Simon, Neal
    Ernst, Monique
    Grillon, Christian
    PSYCHOPHARMACOLOGY, 2021, 238 (09) : 2393 - 2403
  • [2] Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans
    Lago, Tiffany
    Brownstein, Michael
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Simon, Neal
    Grillon, Christian
    Ernst, Monique
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 394 - 394
  • [3] Effects of SRX246, a Vasopressin 1a Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans
    Lago, Tiffany
    Brownstein, Michael
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Simon, Neal
    Ernst, Monique
    Grillon, Christian
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S167 - S168
  • [4] The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease
    Maibach, Hilda T.
    Brownstein, Michael J.
    Hersch, Steven M.
    Anderson, Karen E.
    Itzkowitz, Debra E.
    Damiano, Eve M.
    Simon, Neal G.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):
  • [5] A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment
    Difede, JoAnn
    McAleavey, Andrew A.
    Emrich, Mariel
    Jick, Adina
    Ovalles, Annell
    Wyka, Katarzyna
    Spielman, Lisa
    Olden, Megan
    Peskin, Melissa
    Becket-Davenport, Colleen
    Rubenstein, Amy
    Brownstein, Michael J.
    Damiano, Eve
    Itzkowitz, Debra
    Lu, Shi-fang
    Needell, Nancy J.
    Kocsis, James H.
    Gordon-Elliott, Janna S.
    Simon, Neal G.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [6] Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety
    Bailey, Jayne E.
    Papadopoulos, Andreas
    Diaper, Alison
    Phillips, Suzanne
    Schmidt, M. E.
    van der Ark, P.
    Dourish, Colin T.
    Dawson, Gerard R.
    Nutt, David J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (09) : 1199 - 1206
  • [7] Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury
    Marmarou, Christina R. p
    Liang, Xiuyin
    Abidi, Naqeeb H.
    Parveen, Shanaz
    Taya, Keisuke
    Henderson, Scott C.
    Young, Harold F.
    Filippidis, Aristotelis S.
    Baumgarten, Clive M.
    BRAIN RESEARCH, 2014, 1581 : 89 - 102
  • [8] NMRA-511, a Novel Vasopressin 1a (V1a) Receptor Antagonist Reduces Threat Behaviors in Marmosets and Alters EEG Power Spectra Similarly in Marmosets and Humans
    Wallace, Tanya
    Morrison, Filomene
    Gerrard, Philip
    Ereshefsky, Larry
    Ballard, Michael
    Posener, Joel
    Tracy, Katherine
    Tiller, Jane
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 334 - 334
  • [9] NMRA-511, a Novel Vasopressin 1a (V1a) Receptor Antagonist Reduces Threat Behaviors in Marmosets and Alters EEG Power Spectra Similarly in Marmosets and Humans
    Wallace, Tanya
    Morrison, Filomene
    Gerrard, Philip
    Ereshefsky, Larry
    Ballard, Michael
    Posener, Joel
    Tracy, Katherine
    Tiller, Jane
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 334 - 334
  • [10] A phase 2 study of OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: positive proof-of-concept established in subjects with cirrhosis and hepatorenal syndromeacute kidney injury (HRS-AKI)
    Allegretti, Andrew S.
    Bajaj, Jasmohan
    Bari, Khurram
    Brown, Robert S., Jr.
    Cullaro, Giuseppe
    Ganger, Daniel
    Hassanein, Tarek
    Kemmer, Nyingi
    Khemichian, Saro
    Kwo, Paul Yien
    Lim, Nicholas
    Naqvi, Hasan
    Patidar, Kavish
    Pyrsopoulos, Nikolaos T.
    Rahimi, Robert S.
    Rockey, Don
    Sanyal, Arun J.
    Shetty, Kirti
    Simonetto, Douglas
    Stein, Lance
    Vargas, Hugo
    Zamor, Philippe
    Bernstein, David
    Kjems, Lise
    Lam, Jason
    Reid, Susan
    Wong, Florence
    JOURNAL OF HEPATOLOGY, 2024, 80 : S242 - S243
12